View Item 

Show simple item record

Nirmatrelvir and ritonavir. Information for patients

dc.date.accessioned2022
dc.date.available2022
dc.date.issued2022
dc.identifier.govdocPAHO/HSS/MT/COVID-19/22-0035
dc.identifier.urihttps://iris.paho.org/handle/10665.2/56835
dc.description.abstractThe Pan American Health Organization presents this brochure in order to inform patients and the general public about the combination of nirmatrelvir with ritonavir. This treatment, which requires a prescription, is indicated for mild to moderate cases in people with a positive confirmatory test who are at high risk of progression to severe or critical illness and hospitalization.en_US
dc.language.isoenen_US
dc.publisherPAHOen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 IGO*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/igo/*
dc.subjectNirmatrelviren_US
dc.subjectRitonaviren_US
dc.subjectDrug Interactionsen_US
dc.subjectAntiviral Drugsen_US
dc.subjectCOVID-19en_US
dc.titleNirmatrelvir and ritonavir. Information for patientsen_US
dc.typeInformation kit (folder, banner, brochure)en_US
dc.rights.holderPan American Health Organizationen_US
dc.contributor.corporatenamePan American Health Organizationen_US
paho.isfeatured0en_US
paho.publisher.countryUnited Statesen_US
paho.publisher.cityWashington, D.C.en_US
paho.source.centercodeUS1.1en_US
paho.relation.languageVersion10665.2/56836
paho.contributor.departmentHealth Systems and Services (HSS)en_US
paho.iswhotranslationNoen_US


Files in this item

Thumbnail
Name:
PAHOHSSMTCOVID19220035_eng.pdf
Size:
1.582Mb
Format:
PDF
Description:
English; 2 pages
View/Open

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO